The Latin America, Middle East and Africa Nerve Repair and Regeneration Market is expected to witness market growth of 8.8% CAGR during the forecast period (2022-2028).
Collateral sprouting occurs when just portion of the axons feeding a muscle are injured, and the intact motor axons form sprouts which reinnervate the denervated muscle fibre. As early as 4 days after the injury, these nerve sprouts emerge from the nodes of Ranvier (nodal sprouts) or the nerve terminals (terminal sprouts). Collateral innervation raises the length of the surviving motor units and boosts contractile force by using denervated muscle fibres. From the moment of injury, clinical healing owing to collateral sprouting takes 3-6 months. Even though the muscle as a whole atrophies, compensatory growth of muscle fibres which have retained their axons occurs throughout this time. Improved motor unit firing synchronisation contributes to increased strength.
In opposition to partial or mild nerve injury, where the surviving motor axon initiates collateral sprouting practically instantly, neuronal regeneration begins from the proximal stump just after wallerian degeneration is finished in severe or total injury. Neuronal regrowth relies heavily on Schwann cells. They enhance the migration of nerve sprouts that grow at the regenerated axon tip by dedifferentiating and upregulating the production of adhesion molecules and neurotrophins. Those sprouts subsequently create cords that are oriented around the myelinated axons' initial basal lamina tubes, providing a conduit for new axons to grow. At around 3 months, axon regeneration overlaps with collateral sprouting, but from 6 to 24 months following the damage, axon regeneration is the primary repair strategy, based in particular on the distance the nerve must travel to reach its target muscle.
Dementia is a common disorder in Arab countries, with prevalence rates ranging from 1.1 percent to 2.3 percent among people aged 50 and up, and between 13.5 percent and 18.5 percent among people aged 80 and above, according to studies. These results, however, are similar to those of many other countries around the world. Furthermore, prevalence was seen to differ based on sociodemographic factors. Diabetes mellitus, Obesity, and cardiovascular risk factors are all major dementia risk factors, as are hypertension, low income, and a lack of education. Despite the expanding body of knowledge about the epidemiological distribution and drivers of dementia around the world, studies from the Arab world are few.
According to the WHO, the average growth rate of the ageing population (85 years and older) in various Arab nations is expected to rise by 5% between 2000 and 2050. As a result, age disparities between groups sometimes result in variable prevalence estimates, making it impossible to compare them effectively. A substantial influence is also played by vascular risk factors and hereditary variables. Dementia is more common in the elderly than in people between the ages of 20 and 50. Thus, due to these factors, the regional nerve repair and regeneration market is expected to witness a surge over the forecast period.
The Brazil market dominated the LAMEA Nerve Repair and Regeneration Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $137 Million by 2028. The Argentina market is estimated to grow at a CAGR of 9.4% during (2022 - 2028). Additionally, The UAE market is expected to witness a CAGR of 8.5% during (2022 - 2028).
Based on Surgery, the market is segmented into Neuromodulation Surgery, Direct Neuropathy, Nerve Grafting, and Stem Cell Therapy. Based on Product, the market is segmented into Neuromodulation Surgery Devices and Biomaterials. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Integra Lifesciences Corporation, Medtronic PLC, Axogen, Inc., Stryker Corporation, Checkpoint Surgical, Inc., Polyganics BV, Synovis Micro Companies Alliance, Inc. (Baxter International, Inc.), and OrthoMed, Inc.
Collateral sprouting occurs when just portion of the axons feeding a muscle are injured, and the intact motor axons form sprouts which reinnervate the denervated muscle fibre. As early as 4 days after the injury, these nerve sprouts emerge from the nodes of Ranvier (nodal sprouts) or the nerve terminals (terminal sprouts). Collateral innervation raises the length of the surviving motor units and boosts contractile force by using denervated muscle fibres. From the moment of injury, clinical healing owing to collateral sprouting takes 3-6 months. Even though the muscle as a whole atrophies, compensatory growth of muscle fibres which have retained their axons occurs throughout this time. Improved motor unit firing synchronisation contributes to increased strength.
In opposition to partial or mild nerve injury, where the surviving motor axon initiates collateral sprouting practically instantly, neuronal regeneration begins from the proximal stump just after wallerian degeneration is finished in severe or total injury. Neuronal regrowth relies heavily on Schwann cells. They enhance the migration of nerve sprouts that grow at the regenerated axon tip by dedifferentiating and upregulating the production of adhesion molecules and neurotrophins. Those sprouts subsequently create cords that are oriented around the myelinated axons' initial basal lamina tubes, providing a conduit for new axons to grow. At around 3 months, axon regeneration overlaps with collateral sprouting, but from 6 to 24 months following the damage, axon regeneration is the primary repair strategy, based in particular on the distance the nerve must travel to reach its target muscle.
Dementia is a common disorder in Arab countries, with prevalence rates ranging from 1.1 percent to 2.3 percent among people aged 50 and up, and between 13.5 percent and 18.5 percent among people aged 80 and above, according to studies. These results, however, are similar to those of many other countries around the world. Furthermore, prevalence was seen to differ based on sociodemographic factors. Diabetes mellitus, Obesity, and cardiovascular risk factors are all major dementia risk factors, as are hypertension, low income, and a lack of education. Despite the expanding body of knowledge about the epidemiological distribution and drivers of dementia around the world, studies from the Arab world are few.
According to the WHO, the average growth rate of the ageing population (85 years and older) in various Arab nations is expected to rise by 5% between 2000 and 2050. As a result, age disparities between groups sometimes result in variable prevalence estimates, making it impossible to compare them effectively. A substantial influence is also played by vascular risk factors and hereditary variables. Dementia is more common in the elderly than in people between the ages of 20 and 50. Thus, due to these factors, the regional nerve repair and regeneration market is expected to witness a surge over the forecast period.
The Brazil market dominated the LAMEA Nerve Repair and Regeneration Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $137 Million by 2028. The Argentina market is estimated to grow at a CAGR of 9.4% during (2022 - 2028). Additionally, The UAE market is expected to witness a CAGR of 8.5% during (2022 - 2028).
Based on Surgery, the market is segmented into Neuromodulation Surgery, Direct Neuropathy, Nerve Grafting, and Stem Cell Therapy. Based on Product, the market is segmented into Neuromodulation Surgery Devices and Biomaterials. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Integra Lifesciences Corporation, Medtronic PLC, Axogen, Inc., Stryker Corporation, Checkpoint Surgical, Inc., Polyganics BV, Synovis Micro Companies Alliance, Inc. (Baxter International, Inc.), and OrthoMed, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Surgery
- Neuromodulation Surgery
- Direct Neuropathy
- Nerve Grafting
- Stem Cell Therapy
By Product
- Neuromodulation Surgery Devices
- Biomaterials
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Boston Scientific Corporation
- Integra Lifesciences Corporation
- Medtronic PLC
- Axogen, Inc.
- Stryker Corporation
- Checkpoint Surgical, Inc.
- Polyganics BV
- Synovis Micro Companies Alliance, Inc. (Baxter International, Inc.)
- OrthoMed, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Nerve Repair and Regeneration Market by Surgery
Chapter 5. LAMEA Nerve Repair and Regeneration Market by Product
Chapter 6. LAMEA Nerve Repair and Regeneration Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Boston Scientific Corporation
- Integra Lifesciences Corporation
- Medtronic PLC
- Axogen, Inc.
- Stryker Corporation
- Checkpoint Surgical, Inc.
- Polyganics BV
- Synovis Micro Companies Alliance, Inc. (Baxter International, Inc.)
- OrthoMed, Inc.
Methodology
LOADING...
